Oct 15, 2018 9:26 am EDT SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES)
Sep 4, 2018 8:00 am EDT SCYNEXIS, Inc. Presents Ibrexafungerp Data at the 2018 ESCMID/ASM Conference on Drug Development
Aug 9, 2018 4:15 pm EDT SCYNEXIS Reports Second Quarter 2018 Financial Results and Provides Company Update
Jul 18, 2018 8:05 am EDT The World Health Organization Recognizes New Antifungal Class by Granting "ibrexafungerp" to SCYNEXIS as the International Non-Proprietary Name for SCY-078
Jul 10, 2018 4:05 pm EDT SCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal Candidiasis
Jun 27, 2018 8:00 am EDT SCYNEXIS Announces the Presentation of SCY-078 Data at the Teratology Society 58th Annual Meeting
